Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Astellas Pharma Inc. (ALPMY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Astellas Pharma Inc. is one of 916 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Astellas Pharma Inc. is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ALPMY's full-year earnings has moved 11.6% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ALPMY has returned about 21.3% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of 8% on a year-to-date basis. This shows that Astellas Pharma Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Elevance Health (ELV), has outperformed the sector so far this year. The stock's year-to-date return is 18%.
In Elevance Health's case, the consensus EPS estimate for the current year increased 7.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Astellas Pharma Inc. is a member of the Medical - Drugs industry, which includes 133 individual companies and currently sits at #100 in the Zacks Industry Rank. On average, stocks in this group have lost 4% this year, meaning that ALPMY is performing better in terms of year-to-date returns.
On the other hand, Elevance Health belongs to the Medical Services industry. This 70-stock industry is currently ranked #110. The industry has moved +8.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Astellas Pharma Inc. and Elevance Health as they could maintain their solid performance.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astellas Pharma Inc. (ALPMY): Free Stock Analysis Report
Elevance Health, Inc. (ELV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).